<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317886</url>
  </required_header>
  <id_info>
    <org_study_id>2128</org_study_id>
    <nct_id>NCT03317886</nct_id>
  </id_info>
  <brief_title>Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer</brief_title>
  <official_title>Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the advantage of mesenteric approach during
      pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). The design of this
      study is multicenter randomized clinical trial, comparing oncological and surgical outcomes
      between mesenteric approach and conventional approach during PD for PDAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mesenteric approach starts from dissection of lymph nodes around the superior mesenteric
      artery (SMA) and finally performs Kocher's maneuver during PD. The aims of this approach are
      1) decrease of intraoperative blood loss volume, 2) increase of R0 rate, and 3) prevention of
      squeezing cancer cells out into the vessels. However, there have been no evidence of the
      efficacy of this procedure. Therefore, the aim of this study is to evaluate the efficacy of
      mesenteric approach during PD for PDAC, by multicenter randomized clinical trial comparing
      oncological and surgical outcomes between mesenteric approach and conventional approach
      during PD for PDAC.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 48 months</time_frame>
    <description>survival from surgery to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>up to 24 months</time_frame>
    <description>time for operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time for resection</measure>
    <time_frame>up to 3 months</time_frame>
    <description>time for resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>up to 3 months</time_frame>
    <description>intraoperative blood loss volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood transfusion volume</measure>
    <time_frame>up to 3 months</time_frame>
    <description>transfusion volume required during operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade B/C pancreatic fistula rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>grade B/C pancreatic fistula rate according to International Study Group of Pancreatic Surgery (ISGPS) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of delayed gastric emptying</measure>
    <time_frame>up to 3 months</time_frame>
    <description>rate of delayed gastric emptying according to International Study Group of Pancreatic Surgery (ISGPS) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal hemorrhage rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>abdominal hemorrhage rate according to International Study Group of Pancreatic Surgery (ISGPS) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all morbidity rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>rate of all postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>rate of operative death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diarrhea rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>rate of postoperative rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>pathological R0 rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R1 rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>pathological R1 rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the closest length between surgical margin and cancer cell</measure>
    <time_frame>up to 3 months</time_frame>
    <description>the closest length between surgical margin and cancer cell if R0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of harvested lymph nodes</measure>
    <time_frame>up to 3 months</time_frame>
    <description>number of harvested lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of metastatic lymph nodes</measure>
    <time_frame>up to 3 months</time_frame>
    <description>number of metastatic lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymph node ratio</measure>
    <time_frame>up to 3 months</time_frame>
    <description>number of metastatic lymph nodes divided by number of harvested lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>survival from operation date to recurrence date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>site of initial recurrence</measure>
    <time_frame>up to 24 months</time_frame>
    <description>site of initial recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Pancreaticoduodenectomy</condition>
  <condition>Mesenteric Approach</condition>
  <arm_group>
    <arm_group_label>mesenteric approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreaticoduodenectomy</intervention_name>
    <description>pancreaticoduodenectomy for pancreatic ductal adenocarcinoma</description>
    <arm_group_label>mesenteric approach</arm_group_label>
    <arm_group_label>conventional approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who are scheduled to undergo pancreaticoduodenectomy for resectable or
             borderline resectable (only portal vein invasion) pancreatic ductal adenocarcinoma.

          2. Patients whose Eastern Cooperative Oncology Group performance status are 0 or 1.

          3. Patients who are 20 years or older.

          4. Patients who have adequate organ function.

          5. Patients who understand sufficiently the study to provide written informed consent

        Exclusion Criteria:

          1. Patients who have severe ischemic cardiovascular disease

          2. Patients who have liver cirrhosis or active hepatitis

          3. Patients who need oxygen due to interstitial pneumonia or lung fibrosis

          4. Patients who receive dialysis due to chronic renal failure

          5. Patients who need surrounding organ resection

          6. Patients who need artery reconstruction

          7. Patients who are diagnosed as positive para-aortic lymph node metastases based on
             preoperative imaging

          8. Patients who have active multiple cancer that is thought to influence the occurrence
             of adverse events

          9. Patients who take steroid for the long period that is thought to influence the
             occurrence of adverse events

         10. Patients who undergo laparoscopic or laparoscopy-assisted pancreaticoduodenectomy

         11. Patients who cannot understand ths study due to psychotic disease or psychological
             symptoms

         12. Patients whose preoperative biopsy tissues are diagnosed as other pathological
             findings than pancreatic ductal adenocarcinoma

         13. Patients who underwent gastrectomy or colon/ rectum resection previously

         14. Patients who have severe drug allergy to iodine and gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seiko Hirono, M.D.,PhD</last_name>
    <phone>+81-73-441-0613</phone>
    <email>seiko-h@wakayama-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyusyu University</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masafumi Nakamura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University</name>
      <address>
        <city>Hirakata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masanori Kon</last_name>
    </contact>
    <investigator>
      <last_name>Sohei Satoi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshiaki Murakami</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shimane University</name>
      <address>
        <city>Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshitsugu Tajima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagoshima University</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kousei Maemura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masayuki Sho</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hideo Baba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuhiro Kodera</last_name>
    </contact>
    <investigator>
      <last_name>Suguru Yamada</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Medical University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryosuke Amano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hidetoshi Eguchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga Medical University</name>
      <address>
        <city>Otsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University</name>
      <address>
        <city>Sayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ippei Matsumoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuichi Nagakawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama University</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsutomu Fujii</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroki Yamaue, M.D., PhD</last_name>
      <phone>+81-73-441-0613</phone>
      <email>yamaue-h@wakayama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Seiko Hirono, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manabu Kawai, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ken-ichi Okada, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Motoki Miyazawa, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuji Kitahata, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryohei Kobayashi, M.D., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariko Doi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toshio Shimokawa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroki Yamaue, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 21, 2017</last_update_submitted>
  <last_update_submitted_qc>October 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Hiroki Yamaue</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

